Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    CLBH589H2101
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine

Indicates status has not been verified in more than two years